Soleno Therapeutics (SLNO) Return on Capital Employed: 2014-2017
Historic Return on Capital Employed for Soleno Therapeutics (SLNO) over the last 3 years, with Dec 2017 value amounting to -0.39%.
- Soleno Therapeutics' Return on Capital Employed rose 159.00% to -0.39% in Q4 2017 from the same period last year, while for Dec 2017 it was -0.39%, marking a year-over-year increase of 159.00%. This contributed to the annual value of -0.36% for FY2018, which is 23.00% up from last year.
- Per Soleno Therapeutics' latest filing, its Return on Capital Employed stood at -0.39% for Q4 2017, which was down 18.95% from -0.33% recorded in Q3 2017.
- Soleno Therapeutics' 5-year Return on Capital Employed high stood at 2.20% for Q2 2015, and its period low was -5.25% during Q3 2015.
- Moreover, its 3-year median value for Return on Capital Employed was -1.41% (2015), whereas its average is -1.41%.
- Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Return on Capital Employed was 291bps (2016), while the steepest drop was 458bps (2016).
- Quarterly analysis of 4 years shows Soleno Therapeutics' Return on Capital Employed stood at -1.37% in 2014, then plummeted by 130bps to -2.67% in 2015, then soared by 69bps to -1.98% in 2016, then skyrocketed by 159bps to -0.39% in 2017.
- Its last three reported values are -0.39% in Q4 2017, -0.33% for Q3 2017, and -0.27% during Q2 2017.